Literature DB >> 16474316

An APRIL to remember: novel TNF ligands as therapeutic targets.

Stacey R Dillon1, Jane A Gross, Stephen M Ansell, Anne J Novak.   

Abstract

Since their discovery in 1998, the two TNF family members APRIL and BLyS/BAFF have received increasing attention. In addition to regulating normal B-cell development and immune responses, these molecules might be crucial in a diverse set of diseases, including autoimmunity and cancer. Although more has been published about the general biology of BLyS/BAFF than that of APRIL, many recent articles have described novel APRIL biology. Here we focus on APRIL, exploring its normal and pathological functions, and comparing the therapeutic molecules currently under development that target BLyS/BAFF alone, or APRIL and BLyS/BAFF together.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16474316     DOI： 10.1038/nrd1982

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  103 in total

1.  Immune receptor expressed on myeloid cells 1 (IREM-1) inhibits B cell activation factor (BAFF)-mediated inflammatory regulation of THP-1 cells through modulation of the activities of extracellular regulated kinase (ERK).

Authors:  S-M Lee; Y-P Nam; K Suk; W-H Lee
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

2.  Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.

Authors:  Montserrat Cols; Carolina M Barra; Bing He; Irene Puga; Weifeng Xu; April Chiu; Wayne Tam; Daniel M Knowles; Stacey R Dillon; John P Leonard; Richard R Furman; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

3.  TNF superfamily member 13, APRIL, inhibits allergic lung inflammation.

Authors:  Yanping Xiao; Seiichi Motomura; Vadim Deyev; Eckhard R Podack
Journal:  Eur J Immunol       Date:  2010-12-01       Impact factor: 5.532

Review 4.  Innate signaling networks in mucosal IgA class switching.

Authors:  Alejo Chorny; Irene Puga; Andrea Cerutti
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

5.  Amelioration of colorectal cancer using negative lipidoid nanoparticles to encapsulate siRNA against APRIL by enema delivery mode.

Authors:  Weifeng Ding; Guihua Wang; Keke Shao; Feng Wang; Hua Huang; Shaoqing Ju; Hui Cong; Huimin Wang
Journal:  Pathol Oncol Res       Date:  2014-04-26       Impact factor: 3.201

6.  B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells.

Authors:  V Gorbacheva; K Ayasoufi; R Fan; W M Baldwin; A Valujskikh
Journal:  Am J Transplant       Date:  2014-12-12       Impact factor: 8.086

7.  Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers.

Authors:  Alain Munafo; Anthony Priestley; Ivan Nestorov; Jennifer Visich; Mark Rogge
Journal:  Eur J Clin Pharmacol       Date:  2007-05-01       Impact factor: 2.953

Review 8.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

Review 9.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

10.  The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function.

Authors:  John J Lee; Ingrid Rauter; Lilit Garibyan; Esra Ozcan; Tatyana Sannikova; Stacey R Dillon; Anthony C Cruz; Richard M Siegel; Richard Bram; Haifa Jabara; Raif S Geha
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.